7/1/2015. Objectives. Host Factors LATE EFFECTS OF RADIOTHERAPY IN CHILDHOOD CANCER. Chronic Conditions in Adult Survivors
|
|
- April Miller
- 5 years ago
- Views:
Transcription
1 LATE EFFECTS OF RADIOTHERAPY IN CHILDHOOD CANCER ARNOLD C. PAULINO, M.D. PROFESSOR DEPARTMENT OF RADIATION ONCOLOGY MD ANDERSON CANCER CENTER Objectives At the end of the presentation, the participant should be able to Gain an appreciation for the impact of treatmentrelated late effects on mortality and morbidity of long-term childhood cancer survivors Gain an understanding of host, tumor and treatment parameters which can impact on late effects of treatment Gain an understanding of trends in pediatric oncology on how late effects can be minimized or avoided Cause of Mortality in 5-Year Survivors of Childhood Cancer Recurrent Cancer Second Malignancy/ Neoplasm Cardiac Toxicity Pulmonary Disease Other Sequelae Non- Treatment Related Childhood Cancer Survivor Study N = 2823 Piedmont Region, Italy N = 143 British Columbia, Canada N = % 15% 7% 2% 4% 15% 62.2% 12.6% 1.4% NA 8.4% 15.4% 69.1% 7.7% 4.4% 2.2% 5.5% 11.1% Chronic Conditions in Adult Survivors Host Factors Condition Relative Risk of Grade 3 or 4 Complication as Compared to Siblings Major Joint Replacement Congestive Heart Failure 15.1 Second malignant neoplasm 14.8 Cognitive dysfunction, severe 10.5 Coronary artery disease 10.4 Age of the Child Gender Genetic Predisposition Comorbid Disease Cerebrovascular Accident 9.3 Renal failure or dialysis 8.9 Hearing loss not corrected by aid 6.3 Legally blind or loss of eye 5.8 Ovarian failure 3.5 Oeffinger KC et al. N Engl J Med 2006; 355:
2 Tumor Parameters Treatment Parameters Direct tissue effects (extent of organ invasion) examples: parameningeal rhabdomyosarcoma with unilateral hearing loss, bone and soft tissue sarcomas causing cord compression Indirect mechanical effects examples: brain tumors causing hydocephalus, abdominal sarcomas causing renal failure by compression of ureters Volume Irradiated Total Dose Fraction Size Use of Concurrent Chemotherapy Timing of Chemotherapy and Radiotherapy (methotrexate and cisplatin) Use of Surgery AGE GENDER HEREDITY Different organs are maturing at different times during childhood Host Parameters ECONOMIC STATUS RACE Brain Most sensitive during fetal period but postnatally during first few years of life Most neurons present at birth but brain is still in an unfinished state Increase in axonal growth, dendritic arborization and synaptogenesis 2
3 Brain Impact of Age in Ependymoma Myelin formation well developed at the second year of life and continues in some tracts until years By age 6, most children have attained adult brain size Neurogenesis still occurs in adults mainly in hippocampus von Hoff K et al. BMC Cancer 2008; 8:15 Impact of Age in Low Grade Glioma Reduced Craniospinal Dose in Medulloblastoma Rate of IQ Change -4.3 FSIQ points/year -4.2 VIQ points/year -4.0 NVIQ points/year Females (p=0.008) were more subject to have a VIQ decline Younger children (< 7 years) were more likely to have NVIQ decline Merchant TE et al. J Clin Oncol 2009; 27: Ris MD et al. J Clin Oncol 2001; 19: Musculoskeletal Bone Accelerated growth at birth to 5 years and during puberty Bone density is at a maximum at 18 to 20 years 10% of bone is remodeled annually With age, activity of osteoclasts increase and of osteoblast decrease Radiation injury depends on portion of bone irradiated Epiphysis arrested chondrogenesis Metaphysis deficient absorptive process in calcified bone and cartilage Diaphysis alteration in periosteal activity causing abnormal bone modeling 3
4 Height Deficit from Radiotherapy Gonadal Age at treatment (years) Height deficit (cm) after 10 Gy Height deficit (cm) after 20 Gy Height deficit (cm) after 30 Gy Hogeboom CJ et al. Med Pediatr Oncol 2001; 36: Secondary Breast Cancer Ovarian Failure 9.2% incidence of breast cancer at 20 years after radiotherapy for Hodgkin lymphoma Higher incidence of breast cancer in those treated from years compared to < 12 years (Constine et al.) Higher incidence of breast cancer in those treated with RT from years compared to < 10 years (Bhatia et al., Late Effects Study Group) Adults are more susceptible to sterility than children because of limited number of oocytes Effective sterilizing dose (ESD) to the ovary after fractionated RT decreased with increasing age at radiotherapy ESD birth 20.3 Gy 10 years 18.4 Gy 20 years 16.5 Gy 30 years 14.3 Gy Wallace WHB et al. Int J Radiat Oncol Biol Phys 2005, 62: Gender and Late Effects Cranial Irradiation and ALL Tumor Gender Late Effect Acute lymphoblastic leukemia (ALL) Acute lymphoblastic leukemia (ALL) Female > Male Female > Male Cognitive Deficit Height Impairment Hodgkin Lymphoma Female > Male Secondary Tumors Hodgkin lymphoma Female > Male Hypothyroidism 51 patients treated on Dana-Farber protocol. Children either received 18 Gy (standard risk) or 28 Gy (high risk) 50% of girls vs. 14% of boys had IQ < 90 on follow-up (p = 0.01) Increased dose intensity of iv methotrexate was associated with lower IQ, but only in girls Waber DP et al. J Clin Oncol 1992; 10:
5 Cranial Irradiation and ALL Genetic Predisposition Cross sectional study from Childhood Cancer Survivor Study comparing adult height of ALL children (n = 2434) compared to siblings (n = 3009) Risk factors for short stature were higher dose cranial RT (> 20 Gy), any RT to spine and female sex Neurofibromatosis, type 1 and 2 Bilateral Retinoblastoma Gorlin syndrome Li Fraumeni syndrome Chow EJ et al. J Pediatr 2007; 150:370-5 NF-1 and Optic Pathway Glioma NF-1 and Moyamoya Syndrome N = 40 No Radiotherapy 721 person-years of follow-up 8 (20%) developed 9 tumors N = 18 Radiotherapy 308 person-years of follow-up 9 (50%) developed 12 tumors Sharif S et al. J Clin Oncol 2006; 24: Desai S et al. Int J Radiat Oncol Biol Phys 2006; 65: Basal cell carcinomas following craniospinal irradiation for medulloblastoma in Gorlin Syndrome Li Fraumeni Syndrome Of 200 Li Fraumeni syndrome family members diagnosed with cancer, 30 (15%) developed second, 8 (4%) developed third and 4 (2%) developed fourth cancers. Cumulative probability of Second cancer at 30 years: 57% Third cancer at 10 years: 38% RR of second cancer varied according to age at first cancer 83: ages 0-19 years 9.7: ages years 1.5: age 45 years or more Mitchell G et al. Clin Oncol 2005; 17:650-4 Happle R. J Am Acad Dermatol 1999; 41: Hisada M et al. JNCI 1998; 90:
6 Retinoblastoma Treatment Parameters 40-year incidence of secondary malignancy 40-year incidence of secondary malignancy in irradiated patients Standardized incidence ratio (SIR) (median follow-up of 21.9 years) Hereditary RB Non-hereditary RB 28.0% 1.4% 33.2% 13.3% SURGERY RADIOTHERAPY CHEMOTHERAPY Marees T et al. J Natl Cancer Inst 2008; 100: Impact of Surgery Scoliosis in Neuroblastoma Paulino AC and Fowler BZ. Int J Radiat Oncol Biol Phys 61, 2005 Renal Failure in Wilms Tumor Impact of Chemotherapy No of pts No of pts with renal failure Incidence of Renal Failure (%) at 2 years 4 years 16 years Unilateral Bilateral NWTS NWTS NWTS NWTS _ Ritchey ML et al. Med Pediatr Oncol 1996; 26:
7 Congestive Heart Failure Leukoencepalopathy 4.4% at 20 years for those initially treated with doxorubicin (NWTS) 17.4% at 20 years for those treated with doxorubicin for first or subsequent relapse Relative risk of CHF was increased in those receiving whole lung irradiation (RR 1.6/10 Gy) and left abdominal irradiation (RR 1.8/10 Gy) < 2% INTRAVENOUS METHOTREXATE >40-80 mg/m2/week CRANIAL RADIOTHERAPY > 20 Gy < 1% 15% 5% 45% 2% < 1% INTRATHECAL METHOTREXATE > 50 mg Green DM et al. J Clin Oncol 2001; 19: Griffin TW. Radiation damage to nervous system, 1980 Hypothyroidism Strategies in Pediatric Oncology Delaying radiotherapy until child is at least 3 years old (brain tumors) Using hyperfractionated radiotherapy Using radioprotecting agents Decreasing radiotherapy doses and volumes by including chemotherapy in treatment regimen Decreasing radiotherapy volumes from high and low dose radiation using newer technologies Eliminating radiotherapy in favorable subsets of patients Paulino AC. Int J Radiat Oncol Biol Phys 53:543-7, 2002 RADIOTHERAPY IN INFANTS WITH BRAIN TUMORS Delaying or omitting radiotherapy CURE COGNITIVE DEFICIT ENDOCRINOPATHY GROWTH RETARDATION SECONDARY MALIGNANCY Popular approach in the 80s and 90s particularly in children < 3 years with brain tumors Craniospinal radiotherapy is delayed until patient is 3 years or older in medulloblastoma Involved field radiotherapy delayed until patient in 3 years or older in ependymoma, malignant glioma 7
8 Baby POG Study (Medulloblastoma) Infant Studies in Ependymoma 62 children received 2 rounds of 2 cycles of VCR, CPM followed by 1 cycle of VP-16 and CDDP after resection Chemotherapy given from months until child turned 3 years 1- and 2-year PFS rates were 42% and 34% Baby POG study: 1 and 2 year progression free survival rates were 58% and 42% French Society Pediatric Oncology: 4 year progression free survival after resection and chemotherapy: 22% Duffner PK et al. N Engl J Med, 1993; 328: Ependymoma Ependymoma St. Jude study of 88 children treated with 3D conformal RT Dose 50.4 Gy (n = 15, all < 18 months) to 59.4 Gy Median age at RT: 2.85 years Clinical target volume was tumor bed + residual tumor with a 10 mm margin. Planning target volume was CTV with a 3 to 5 mm margin Merchant TE et al. J Clin Oncol 2004; 22: Merchant TE et al. J Clin Oncol 2004; 22: Ewing Sarcoma of Extremity Use of Hyperfractionated Radiation Therapy Conventional Hyperfractionated P-value Local Control 77% 81% n.s. Fractures 5/14 0/17.01 Range of motion (degree loss) Muscle atrophy (circumference loss) 21% 8%.004 Bolek TW et al. Int J Radiat Oncol Biol Phys 1996; 35:
9 Hypothyroidism in Medulloblastoma Hyperfractionated Radiotherapy in Pediatric Oncology Tumor Type Conventional Hyperfractionated Outcome Rhabdomyosarcoma (Group III) IRS-IV 50.4 Gy in 28 fractions at 1.8 Gy 59.4 Gy in 54 fractions at 1.1 Gy BID No difference Brainstem glioma POG 54 Gy in 30 fractions at 1.8 Gy 70.2 Gy in 60 fractions at 1.17 Gy BID No difference P = 0.02 Ewing Sarcoma CESS (postoperative) to 60 Gy (definitive) at 1.8 to 2.0 Gy 44.8 (postoperative) to 60.8 Gy (definitive) at 1.6 Gy BID (up to 44.8 Gy then conventional fractionation) given at 3 week intervals No difference Acute Lymphoblastic Leukemia DFCI Consortium 18 Gy in 10 fractions at 1.8 Gy 18 Gy in 20 fractions at 0.9 Gy BID No difference Medulloblastoma (Standard-Risk) HIT-SIOP PNET Gy in 13 fractions to craniospinal axis followed by 32.4 Gy boost to posterior fossa (total dose: 55.8 Gy in 31 fractions at 1.8 Gy) 36 Gy in 30 fractions to craniospinal axis followed by 24 Gy boost to posterior fossa and 8 Gy tumor bed boost (total 68 Gy in 68 fractions at 1 Gy BID) No difference Chin D et al. Cancer 1997; 80: Amifostine Use of Radioprotectors Phosphorothioate radioprotector prodrug that is unreactive and penetrates poorly into cells until dephosphorylated by enzyme alkaline phosphatase to active metabolite WR-1065 Protector for radiotherapy and chemotherapy COG ARAR0331: Nasopharyngeal Cancer Ototoxicity in Medulloblastoma Multi-institution study (SJMB96 and SJMB03) All patients received cisplatin and radiotherapy (CSI followed by posterior fossa boost or tumor bed boost) Amifostine given before and 3 hours into cisplatin administration Proportion with >Grade 3 Ototoxicity at 1 year posttherapy Amifostine 9/62 (14.5%) No Amifostine 13/35 (37.1%) p = Fouladi M et al. J Clin Oncol 2008; 26:
10 Ototoxicity in Medulloblastoma Children s Hospital of Philadelphia 78% of patients developed significant hearing loss despite amifostine Radiotherapy boost was conventional Texas Children s Hospital All patients received IMRT boost to either posterior fossa or tumor bed + margin Four of 19 (21%) treated with amifostine and 7/25 (28%) who did not have amifostine developed > grade 3 hearing loss (p = n.s.) Reducing Radiotherapy Dose and Volume with Addition of Chemotherapy Fisher MJ et al. Pediatr Blood Cancer 2004; 43:780-4 Paulino AC et al. Int J Radiat Oncol Biol Phys 2010; 78: Wilms Tumor (NWTS-3) Scoliosis and Radiotherapy Dose Treatment Percent alive at 2 years Dose N % Scoliosis N 10 yrs 15 yrs AMD + VCR cgy 88.3% AMD + VCR cgy 91.0% AMD + VCR + ADR cgy 92.7% < 1200 cgy 12 1 (8.3) cgy 11 5 (45.5) AMD + VCR + ADR cgy 93.1% > 2400 cgy (63.2) Thomas PRM et al. Cancer 1991; 68: Paulino AC et al. Int J Radiat Oncol Biol Phys 2000; 46: Medulloblastoma Neurocognitive Effects For decades, standard treatment after resection was CSRT to 36 Gy followed by PF boost Now, standard treatment after resection for standard-risk pts is CSRT to 23.4 Gy followed by boost and chemotherapy N Older Average Risk Intercept Slope Points/ yr Older High Risk Intercept Slope Points/ yr Younger Average Risk Intercept Slope Points/ Yr Younger High Risk Intercept Slope Points/ Yr IQ Reading Spelling Math Mulhern RK et al. J Clin Oncol 2005; 23:
11 ACNS0031 (Standard-risk Medulloblastoma) Medulloblastoma Age 3 to 7 years Average Risk: 23.4 Gy to craniospinal axis, Gy to tumor bed CSRT 18 Gy CSRT 23.4 Gy PFRT 23.4 Gy IFRT 55.8 Gy PFRT 55.8 Gy IFRT 55.8 Gy PFRT 55.8 Gy Age > 8 years CSRT 23.4 Gy IFRT 55.8 Gy PFRT 55.8 Gy Mulhern RK et al. Lancet Oncol 2004, 5: Intracranial Germinoma ACNS0232 Standard treatment for M0 Germinoma was craniospinal or whole brain RT followed by boost Now, current treatments include whole ventricular RT followed by boost or neoadjuvant chemotherapy followed by involved field RT Germinoma M0 Disease Radiotherapy Alone Neoadjuvant chemotherapy Whole Ventricular (24 Gy) (carboplatin/etoposide x 2) Followed by involved field (cisplatin/cyclophosphamide (21Gy) x 2) CR Involved field 30 Gy PR, SD, PD Whole Ventricular (24 Gy) Followed by involved field (21Gy) Germinoma Germinoma: Patterns of Failure WB/WV 24 Gy followed by 16 Gy boost vs. focal RT 45 Gy Four courses of chemotherapy followed by XRT to initial tumor volume + 2cm safety margins to 40 Gy Rogers SJ et al. Lancet Oncol 2005; 6: Alapetite C et al. Neuro-Oncology 2010; 12:
12 Hodgkin lymphoma Hodgkin lymphoma Standard treatment before was subtotal nodal RT (doses 36 to 44 Gy) Late effects were significant including extensive musculoskeletal toxicity and second malignancies Current approach is combination chemotherapy followed by involved field radiotherapy (dose 15 to 25.5 Gy) DeBruin ML et al. J Clin Oncol 27: , 2009 Hodgkin lymphoma Reducing High Dose Radiotherapy Volume with Newer Technology O'Brien MM et al. J Clin Oncol 2010; 28: Ototoxicity Ototoxicity and Medulloblastoma Known complication of cisplatin chemotherapy Can occur after radiotherapy When combined together (RT + cisplatin chemotherapy) will have higher incidence of high grade toxicity Huang E et al. Int J Radiat Oncol Biol Phys 2002; 52:
13 Ototoxicity and IMRT in Medulloblastoma Conventional RT N=11 IMRT N=15 IMRT N=88* Median follow-up (months) Mean dose to cochlea Gy ( ) Gy ( ) (standard risk), 43 Gy (high risk) Mean cisplatin Dose 220mg/ m 2 ( ) 290mg/ m 2 ( ) Grade 0 Pediatric Oncology Group Ototoxicity Grade (number of patients) Grade 1 Grade 2 Grade 3 Grade % % 300 mg/ m 2 * Number of ears 18% Reducing Low Dose Radiotherapy Volume with Newer Technology Huang E et al. IJROBP 2002; 52: , Paulino AC et al. IJROBP 2010; 78: Secondary Malignancy Proton Therapy Tumor Source Incidence Wilms tumor National Wilms Tumor Study 1.6% at 15 years Group Acute lymphoblastic leukemia Childrens Cancer Group 1.3% at 10 years Hodgkin lymphoma Stanford University 9.7% for men, 16.8% for women, 9.2% breast cancer at 20 years Hodgkin lymphoma Late Effects Study Group 10.6% at 20 years, 26.3% at 30 years Retinoblastoma Memorial Sloan Kettering 51% for hereditary and 5% for non-hereditary at 50 years Rhabdomyosarcoma Intergroup Rhabdomyosarcoma Studies I and II 1.7% at 10 years Primary Brain tumor St. Jude Children s Research Hospital 4% at 15 years (malignant tumors) Retinoblastoma and Secondary Malignancy Retrospective study of 86 children treated at MGH from with protons (n = 55) or photons (n = 31) Median follow-up is 6.9 years for protons and 13.1 years for photons 10-year incidence of SMN in RT field was 0% vs. 14% (p = 0.015) and 5% vs. 14% (p = 0.12) for all SMN Int J Radiat Oncol Biol Phys 87(2), 2013 Sethi RV et al. Cancer 2013 Epub 13
14 Ependymoma and Protons 70 pediatric patients treated at MGH Median age at RT was 38 months Two-thirds had gross total resection Median follow-up: 46 months 3-year PFS was 54% vs. 88% for STR and GTR Eliminating Radiotherapy in Favorable Subsets of Patients MacDonald SM et al. Neur-Oncologyy 2013; 15: Wilms Tumor (NWTS-3) Whole Lung Irradiation for Wilms Tumor Treatment Percent alive at 2 years AMD + VCR 98.6% AMD + VCR cgy 98.4% AMD + VCR + ADR 95.5% AMD + VCR + ADR cgy 93.5% POTENTIAL TOXICITIES Pneumonitis Cardiac Toxicity Height Impairment Breast, Bone and Soft Tissue Hypoplasia Secondary Cancer (Breast, Thyroid, Lung) Thomas PRM et al. Cancer 1991; 68: Wilms Tumor and Lung Metastasis CT Only Lung Mets (NWTS-4 and -5) Chest X-ray negative, CT scan positive lung nodules Chemotherapy No. of pts 2 year RFS (%) 5 year RFS (%) P-value 4-year Event-Free Survival 4-year Overall Survival Actinomycin-D and Vincristine Actinomycin-D Vincristine and Doxorubicin Whole lung XRT 89% 91% No whole lung XRT 80% 85% P = 0.23 P = 0.41 Radiotherapy Whole Lung Radiotherapy No Whole Lung Radiotherapy No. of pts 2 year RFS (%) 5 year RFS (%) P-value 0.38 Meisel JA et al. Int J Radiat Oncol Biol Phys 1999; 44:
15 Wilms Tumor and Lung Metastasis Hodgkin Lymphoma Study Eligible Patients Chemotherapy Further Treatment Childrens Oncology Group AHOD431 HOD08 First International Intergroup Study Stage IA, IB Non-bulky Stage IA, IB Non-bulky, < 3 nodal regions, no E Stage IA, IB, IIA, no E AV-PC x 3 cycles (adriamycin, vincristine, prednisone, cyclophosphamide) Stanford V x 8 weeks OEPA X 2 cycles (vincristine, etoposide, prednisone, adriamycin) PR: 21 Gy IFRT CR: Observation PR: 25.5Gy IFRT CR: Observation PR: IFRT CR: Observation Molecular Variants of Medulloblastoma Medulloblastoma Molecular Subtypes Northcott PA et al. J Clin Oncol 2011; 29: Pfister SM et al. Acta Neuropathol 2010; 120: Long-Term Follow-Up Guidelines 15
16 P.E.N.T.E.C. Pediatric Normal Tissue Effects in the Clinic (PENTEC) Pediatric version of QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic) which was published in the Int J Radiat Oncol Biol Phys volume 76, #3 Sep 2010 Headed by Dr. Louis Constine Summary Late effects of treatment are an important cause of chronic problems and death in survivors of childhood cancer Late effects of radiotherapy can be dose and volume related and can be influenced by the use of other treatments such as chemotherapy and surgery Summary The age of the child is an important factor in the development of late effects of treatment Newer methods of radiotherapy delivery are currently being used which can impact on late toxicity 16
7/1/2015. Radiotherapy in Infant Brain Tumors. Goals and Objectives. Primary Brain and CNS Tumors (0-14 years) Brain Tumors (1 to 4 years)
Radiotherapy in Infant Brain Tumors ARNOLD C. PAULINO, M.D. PROFESSOR OF RADIATION ONCOLOGY MD ANDERSON CANCER CENTER AND TEXAS CHILDREN S HOSPITAL Radiotherapy in Infant Brain Tumors 1. Try to Avoid Irradiation
More informationState of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center
State of the Art Radiotherapy for Pediatric Tumors Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center Introduction Progress and success in pediatric oncology Examples of low-tech and high-tech
More informationSecond Neoplasms Working Group. CCSS Investigators Meeting June 2017
Second Neoplasms Working Group CCSS Investigators Meeting June 2017 Second Neoplasms Working Group Overview Ongoing review, adjudication and entry of reported neoplasms into data set Initial review of
More information11/27/2017. Proton Therapy for Brain Tumors: Hope or Hype? Financial Disclosures. Objectives. None
Proton Therapy for Brain Tumors: Hope or Hype? 1 Financial Disclosures None 2 Objectives Discuss the rationale and evidence for proton therapy in children and adults Discuss the late effects that can be
More informationMedical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationEvidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.
Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility
More informationTreatment strategies to reduce radiotherapy late effects in children
J Radiat Oncol (2013) 2:121 128 DOI 10.1007/s13566-012-0075-2 REVIEW Treatment strategies to reduce radiotherapy late effects in children Arnold C. Paulino Received: 16 October 2012 / Accepted: 22 October
More informationCarol Marquez, M.D. Department of Radiation Medicine OHSU
Carol Marquez, M.D. Department of Radiation Medicine OHSU JL is a 8 year old boy who presented with coordination problems in using his right hand (difficulty tying his shoes) in January 2011. Imaging revealed
More informationLong term toxicity of treatment. Laurence Brugieres Children and Adolescent Oncologic department
Long term toxicity of treatment Laurence Brugieres Children and Adolescent Oncologic department Most TYA with cancer are cured from their malignancy TRAMA 2016 2 What are the consequences of cancer treatment?
More informationIAEA Pediatric Radiation Oncology Training Dr Laskar Version 1 June 2009 RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE
RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE THOMAS HODGKIN 1832 On Some Morbid Appearances of the Absorbent Glands & Spleen GLOBAL INCIDENCE Region Cases per 100,000 children United States 0.5 European
More informationExploring the potential for clinical introduction of hippocampal-sparing IMPT of pediatric medulloblastoma - Past present and future
Exploring the potential for clinical introduction of hippocampal-sparing IMPT of pediatric medulloblastoma - Past present and future Daniel Gasic Disclosure Nothing to disclose Introduction Background
More informationProton Therapy for Ependymoma and Craniopharyngioma at the University of Florida: Lessons Learned About Efficacy and Toxicity
Proton Therapy for Ependymoma and Craniopharyngioma at the University of Florida: Lessons Learned About Efficacy and Toxicity Danny Indelicato, MD Mendenhall Chair of Pediatric Radiotherapy University
More informationCCSS Neurology Committee Report: 6/08
Neurology Committee Report: 6/08 Roger J. Packer, MD Executive Director Neuroscience and Behavioral Medicine Chairman, Neurology Director, Brain Tumor Institute Children s s National Medical Center Washington,
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL 1. Study title: Subsequent neoplasms among survivors of childhood cancer not previously treated with radiation 2. Working group and investigators:
More informationPEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP. Denise Rokitka, MD, MPH
PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP Denise Rokitka, MD, MPH Objectives Describe incidence of childhood cancer and survival rates and causes of early mortality. Understand the late effects of cancer
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationProfessor Maurice Tubiana
Professor Maurice Tubiana The French way of life Dr. Odile Schweisguth Pediatric Radiation Oncology Daniele Sarrazin Pediatric Radiation Oncology Stanford Visitors from France A Massiot 1958 Courbevoie
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Long-Term Outcomes of Childhood Central Nervous System Tumor Survivors: A Report from the Childhood Cancer Survivor Study Working Group
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationBrain Tumors in Children
Brain Tumors in Children Michael A. Grotzer University Children s Hospital of Zurich, Switzerland Incidence of Childhood Cancer CNS Tumors Acute lymphoblastic Leukemia Neuroblastoma Non-Hodgkin Lymphoma
More informationUpdate on Pediatric Brain Tumors
Update on Pediatric Brain Tumors David I. Sandberg, M.D. Director of Pediatric Neurosurgery & Associate Professor Dr. Marnie Rose Professorship in Pediatric Neurosurgery Pre-talk Questions for Audience
More informationChronic Disease Working Group CCSS Investigator Meeting 2015
Chronic Disease Working Group CCSS Investigator Meeting 2015 Kevin Oeffinger Charles (Chuck) Sklar Chronic Disease Working Group Next 10 yrs of CCSS may be more significant than the previous 10 yrs CCSS
More informationPEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
More information7/31/2018. Research Activities: Imaging for RT Image Guidance for Pediatric Radiotherapy. Chia-ho Hua, PhD. Outline
Research Activities: Imaging for RT Image Guidance for Pediatric Radiotherapy Chia-ho Hua, PhD Chia-ho Associate Hua, Member PhD St. Jude Children s Research Hospital AAPM-COG Joint Session, 60 th Annual
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationDisclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
ALL in AYAs: Health Outcomes as a Criterion for Selecting Optimal Therapy David R. Freyer, DO, MS Director, Survivorship and Supportive Care Program, Children s Center for Cancer and Blood Diseases, Children
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationGoals and Objectives. Historical Background. Historical Background. Incidence. Epidemiology 7/1/2015 ROLE OF RADIOTHERAPY IN WILMS TUMOR
Goals and Objectives ROLE OF RADIOTHERAPY IN WILMS TUMOR Arnold C. Paulino, M.D. Professor of Radiation Oncology MD Anderson Cancer Center To gain an understanding of presentation and work-up of Wilms
More informationCHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in Survivors of Childhood Leukemia with Down Syndrome Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in of Childhood Leukemia with Down Syndrome Analysis Concept Proposal Working Group and Investigators Genetics Working Group & Chronic Disease Working
More informationJournal of Pediatric Sciences
Journal of Pediatric Sciences Role of post-operative radiation therapy in single brain metastasis from clear cell sarcoma in children: a case report with systemic review Fadoua Rais, Naoual Benhmidou,
More information-Proton Beam Therapy in Paediatric Radiation Oncology -
-Proton Beam Therapy in Paediatric Radiation Oncology - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationPediatrics -Proton Beam Therapy in Children -
Pediatrics -Proton Beam Therapy in Children - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far (clinically)
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationChemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Chemotherapy for Childhood and Primitive Neuroectodermal Tumors ROGER J. PACKER, a JONATHAN L. FINLAY b a Department of Neurology, Children s National Medical Center, Washington DC, USA; b Departments
More informationChildhood Cancer Survivor Study Analysis Concept Proposal. Title: Analysis of Late Mortality by Treatment Era.
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Analysis of Late Mortality by Treatment Era Working Group & Investigators: Greg Armstrong Todd Gibson Ann Mertens Wendy Leisenring YutakaYasui
More informationNew RT techniques: childhood cancer
Methodology for literature review, data mining, modeling of dose response in pediatric radiation oncology Søren M Bentzen, Ph.D., D.M.Sc. Division of Biostatistics and Bioinformatics, UMGCC Shared Biostatistics
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Neurologic and Neurosensory Adverse Sequelae in Long-term Survivors of Childhood Brain Tumors: An Update and Expanded Risk Factor Analysis
More informationBackground. Paediatric cancer. Leukaemia
66 9. Paediatric cancer Background Radiotherapy (RT) is an important modality of therapy in the local control of paediatric malignancies and the majority of paediatric tumours are radiosensitive. However,
More informationPediatric electron intraoperative radiotherapy: results and innovations
Pediatric electron intraoperative radiotherapy: results and innovations Felipe A. Calvo ESTRO Hospital General Universitario Gregorio Marañon Madrid, Spain 2017 IOeRT in pediatric cancer: results and innovations
More informationCardiotoxicities of Cancer in Childhood Cancer Survivors
Cardiotoxicities of Cancer in Childhood Cancer Survivors Steven E. Lipshultz, MD Department of Pediatrics Wayne State University School of Medicine Children s Hospital of Michigan Detroit, MI, USA Stages
More informationLessons from treatment of pediatric sarcomas at difficult sites. Dr. Andrea Ferrari Pediatric Oncology Unit Istituto Nazionale Tumori, Milan, Italy
Lessons from treatment of pediatric sarcomas at difficult sites Dr. ndrea Ferrari Pediatric Oncology Unit stituto Nazionale Tumori, Milan, taly Disclosure slide have no potential conflicts of interest
More informationACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
More informationExercise Behavior & Major Cardiac Events: CCSS 1 STUDY TITLE
STUDY TITLE Exercise Behavior & Major Cardiac Events: CCSS 1 Association Between Exercise Behavior and Incidence of Major Cardiac Events in Adult Survivors of Childhood Cancer: A Report from the Childhood
More informationThe technique of craniospinal irradiation of paediatric patients in supine position
The technique of craniospinal irradiation of paediatric patients in supine position Pavel Šlampa 1, Zuzana Seneklova 1, Jiri Simicek 1, Renata Soumarova 1, Petr Burkon 2, Ludmila Burianova 2 1 Masaryk
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationMedulloblastoma / high risk. Radiotherapy in high risk medulloblastoma
Radiotherapy in high risk medulloblastoma PROS Meeting London 4.-6. October 2012 Reference Centre for Radiotherapy, Dept. for Radiation Oncology University of Leipzig Johannisallee 34, 04107 Leipzig/Germany
More informationDisturbances of female reproductive system in survivors of childhood cancer
Disturbances of female reproductive system in survivors of childhood cancer Assoc. Prof. Zana Bumbuliene VU Faculty of Medicine Clinic of Obstetrics and Gynaecology 13 SEP 2014 Introduction Cancer is the
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More information3. BACKGROUND AND RATIONALE
CHILDHOOD CANCER SURVIVOR STUDY Revised Analysis Concept Proposal 10-17 October 12, 2011 1. STUDY TITLE: Growth Hormone Exposure as a risk factor for the development of Subsequent Central Nervous System
More informationNON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA
NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28
More informationTitle: Incidence of chronic disease among childhood cancer survivors by treatment era and temporal trends in treatment exposure
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Incidence of chronic disease among childhood cancer survivors by treatment era and temporal trends in treatment exposure Working Group &
More informationSOLID TUMOURS IN CHILDHOOD
SOLID TUMOURS IN CHILDHOOD Fareed Omar Paediatric Oncology Steve Biko Academic hospital Introduction 1 Introduction Lymphomas and Leukemias make up about 40% of all childhood Cancers (Systemic cancers)
More informationSacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician
Sacral Chordoma: The Loma Linda University Radiation Medicine Experience Kevin Yiee MD, MPH Resident Physician What is a chordoma? 1 st chordoma discovered in clivus by Virchow and Luschka 1856 Rare tumor
More informationAYA & XYZ: Care of the Childhood Cancer Survivor & Adolescent/Young Adult Oncology
AYA & XYZ: Care of the Childhood Cancer Survivor & Adolescent/Young Adult Oncology ST E P H A N I E H O W E G UA R I N O, M D, MSHP, FA A P S I C K L E C E L L PROGRAM C L I N I CAL L EAD, C H R I ST I
More informationComparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationMinesh Mehta, Northwestern University. Chicago, IL
* Minesh Mehta, Northwestern University Chicago, IL Consultant: Adnexus, Bayer, Merck, Tomotherapy Stock Options: Colby, Pharmacyclics, Procertus, Stemina, Tomotherapy Board of Directors: Pharmacyclics
More informationRole of Prophylactic Cranial Irradiation in Small Cell Lung Cancer
Role of Prophylactic Cranial Irradiation in Small Cell Lung Cancer Kazi S. Manir MD,DNB,ECMO,PDCR Clinical Tutor Department of Radiotherapy R. G. Kar Medical College and Hospital, Kolkata SCLC 15% of lung
More informationHodgkin Lymphoma: Umberto Ricardi
Hodgkin Lymphoma: Radiation Volumes Umberto Ricardi Università di Torino The changing role of RT in the cure of HL From Maximal use as a single agent To Combination of chemotherapy and full dose-full volume
More informationDr.Dafalla Ahmed Babiker Jazan University
Dr.Dafalla Ahmed Babiker Jazan University Brain tumors are the second commonest malignancy in children Infratentorial tumors are more common As a general rule they do not metastasize out of the CNS, but
More informationA PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYPERFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY IN STANDARD RISK MEDULLOBLASTOMA
A PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYPERFRACTIONATED VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY IN STANDARD RISK MEDULLOBLASTOMA HIT SIOP PNET 4 A SIOP and GPOH TRIAL START DATE 1 st September
More information1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor Study.
CCSS Analysis Concept Proposal Exercise, Mortality, & Childhood Cancer 1 1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor
More informationJAMES EWING, Endothelial origin. 14 yr Girl
JAMES EWING, 1921 Endothelial origin 14 yr Girl SPECTRUM OF ESFT NEURAL DIFFERENTIATION Least Well EWING S SARCOMA ATYPICAL EWING S SARCOMA PNET Peripheral Neuroepithelioma ASKIN TUMOR (thoraco-pulmonary)
More informationThe Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors
The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors Avner Hershlag MD Professor and Chief Center for Human Reproduction North Shore LIJ Hofsra university School of Medicine
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More informationRadiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationIntroduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT
Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT protocols Tips Leukaemia / lymphoma: ~ 35% acute lymphoblastic
More informationSmall and Big Operations: New Tools of the Trade for Brain Tumors. Disclosure. Incidence of Childhood Cancer
Small and Big Operations: New Tools of the Trade for Brain Tumors Nalin Gupta MD PhD Chief, Division of Pediatric Neurosurgery Departments of Neurosurgery and Pediatrics University of California San Francisco
More informationHigh grade glioma + brainstem glioma
+ brainstem glioma Highly agressive tumours Median survival ca 9-12 months Curative or palliative treatments? Intensity of treatment Side effects Quality of life issues + brainstem glioma Aims of radiotherapy
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationDisclosures 5/13/2013. Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013
Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013 Josh Yamada MD FRCPC Department of Radiation Oncology Memorial Sloan Kettering Cancer Center Disclosures
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Health outcomes among survivors of adolescent and young adult cancer in the Childhood Cancer Survivor Study. Working Group and Investigators:
More informationCancer: recent advances and implications for underwriting
Cancer: recent advances and implications for underwriting Robert Rubens Select 74 Bristol 25 February 2010 Agenda Epidemiology - changing mortality Evidence-base for underwriting breast cancer ovarian
More informationOriginal Study. 40 Clinical Lung Cancer January 2013
Original Study Prophylactic Cranial Irradiation for Patients With Limited-Stage Small-Cell Lung Cancer With Response to Chemoradiation Patricia Tai, 1 Avi Assouline, 2 Kurian Joseph, 3 Larry Stitt, 4 Edward
More informationHot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
More informationWhy? What? When? How? Dr C Fryer FRCPC) Surveillance
Why? What? When? How? Dr C Fryer FRCPC) Surveillance 1 Disclosure; Disclosure; None. I have no conflicts. I have no industry financial relationships. Background: Relapse is the single most likely late
More informationRadiation Related Second Cancers. Stephen F. Kry, Ph.D., D.ABR.
Radiation Related Second Cancers Stephen F. Kry, Ph.D., D.ABR. Objectives Radiation is a well known carcinogen Atomic bomb survivors Accidental exposure Occupational exposure Medically exposed Radiotherapy
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationCHILDHOOD CANCER SURVIVAL STUDY CONCEPT PROPOSAL
Version: March 3, 2006 CHILDHOOD CANCER SURVIVAL STUDY CONCEPT PROPOSAL I- Title: Neurocognitive and Psychosocial Correlates of Adaptive Functioning in Survivors of Childhood Leukemia and Lymphoma. II-
More informationLate effects, health status and quality of life after hemopoietic stem cell
Late effects, health status and quality of life after hemopoietic stem cell transplantation (HSCT) THE 13th ESH-EBMT TRAINING COURSE ON BLOOD AND MARROW TRANSPLANTATION EBMT Slide template Barcelona 7
More informationIntracranial AT RT / radiotherapy. Therapeutic dilemma / radiotherapy
Therapeutic dilemma / radiotherapy Agressive tumour, poor outcome Past treatments based on MB concepts (RT CSA) MB Overall survival Mean age : 6.52 years n=36, 5 year 75% 1. Tumour occurs in the very young
More informationCarbon Ion Radiotherapy for Skull Base and Paracervical Chordomas
Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas Azusa Hasegawa, Jun-etsu Mizoe and Hirohiko Tsujii Research Center Hospital for Charged Particle Therapy National Institute of Radiological
More information7/31/2018 DISCLOSURES INTRODUCTION PARTICULAR NEEDS FOR PEDIATRIC RADIOTHERAPY NONE. Special thanks to Dr. Bruce Thomadsen and the AAPM
PARTICULAR NEEDS FOR PEDIATRIC RADIOTHERAPY John A. Kalapurakal MD, FACR, FASTRO Northwestern University, Chicago, IL Chair, Radiation Oncology, Children s Oncology Group DISCLOSURES NONE INTRODUCTION
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationSubspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident
Subspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident Residents: Pediatric residents at the PL3 level Prerequisites: Successful completion or waiver
More informationOptic Pathway Gliomas, Germinomas, Spinal Cord Tumours. Colin Kennedy March 2015
Optic Pathway Gliomas, Germinomas, Spinal Cord Tumours Colin Kennedy March 2015 Glioma of the optic chiasm. T1-weighted MRI with gadolinium enhancement, showing intense irregular uptake of contrast. The
More informationIntrarenal Extension. sinus
Intrarenal Extension into sinus Document Capsular Penetration sinus 16 Pediatric Renal Tumor Staging Stage I Limited to Kidney & Completely Resected Intact Renal Capsule No Previous Rupture or Biopsy Renal
More informationPEDIATRIC. BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a COMPANION STUDIES
PEDIATRIC BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients. https://clinicaltrials.gov/ct2/show/nct00392327?term=0332&rank=6
More information